PBLA Insider Trading

4.37% of Panbela Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Panbela Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
5/19/2023	Anson Funds Management LP	163,024	$72K	0.0%	N/A	0.971%
5/16/2023	Altium Capital Management LP	335,324	$0.15M	0.1%	N/A	1.998%
11/14/2022	Armistice Capital LLC	2,176,809	$0.59M	0.0%	N/A	5.324%
11/2/2022	Clear Street LLC	110,500	$30K	0.0%	N/A	0.532%
4/7/2022	Fieldpoint Private Securities LLC	62,621	$0.13M	0.0%	-33.7%	0.466%
2/14/2022	Murchinson Ltd.	136,753	$0.24M	0.0%	-8.8%	1.018%
1/24/2022	Fieldpoint Private Securities LLC	94,521	$0.16M	0.0%	-31.8%	0.704%
11/12/2021	Fieldpoint Private Securities LLC	138,660	$0.30M	0.1%	-5.4%	1.033%
11/9/2021	BlackRock Inc.	29,359	$64K	0.0%	+22.2%	0.219%
8/16/2021	Warberg Asset Management LLC	11,567	$33K	0.0%	N/A	0.086%
8/13/2021	Murchinson Ltd.	150,000	$0.43M	0.2%	N/A	1.117%
8/13/2021	Vanguard Group Inc.	217,198	$0.62M	0.0%	+941.8%	1.618%
8/12/2021	Fieldpoint Private Securities LLC	146,500	$0.36M	0.1%	-20.4%	1.091%
8/11/2021	CVI Holdings LLC	41,667	$0.12M	0.0%	N/A	0.310%
8/6/2021	Buckingham Strategic Wealth LLC	24,927	$71K	0.0%	N/A	0.186%
5/19/2021	Squarepoint Ops LLC	15,538	$61K	0.0%	N/A	0.154%
5/18/2021	Verition Fund Management LLC	20,000	$79K	0.0%	-67.0%	0.198%
5/17/2021	Ikarian Capital LLC	345,013	$1.36M	0.0%	N/A	3.420%
4/23/2021	Fieldpoint Private Securities LLC	184,000	$0.73M	0.2%	N/A	1.824%
2/18/2021	Verition Fund Management LLC	60,606	$0.22M	0.0%	N/A	0.628%
2/17/2021	Worth Venture Partners LLC	21,794	$78K	0.1%	N/A	0.226%
2/13/2021	Essex Investment Management Co. LLC	63,079	$0.23M	0.0%	N/A	0.654%
2/1/2021	Brand Asset Management Group Inc.	57,144	$0.20M	0.1%	N/A	0.592%

Data available starting January 2016

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Today's Range

Now: $0.34

$0.31

$0.38

50 Day Range

MA: $0.38

$0.34

$0.45

52 Week Range

Now: $0.34

$0.30

$40.80

Volume

28,439 shs

Average Volume

337,607 shs

Market Capitalization

$1.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Who are the company insiders with the largest holdings of Panbela Therapeutics?: Panbela Therapeutics' top insider shareholders include:
Goldman Sachs Group Inc (Major Shareholder)
Learn More about top insider investors at Panbela Therapeutics.